Synthesis and biological evaluation of novel purinyl quinazolinone derivatives as PI3Kδ-specific inhibitors for the treatment of hematologic malignancies
- 1 September 2021
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry
- Vol. 45, 116312
Abstract
No abstract availableKeywords
Funding Information
- Korea Health Industry Development Institute (HI18C1942)
- Ministry of Health and Welfare (HI18C1942)
This publication has 41 references indexed in Scilit:
- Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeuticsJournal of Hematology & Oncology, 2013
- Development of PI3K inhibitors: lessons learned from early clinical trialsNature Reviews Clinical Oncology, 2013
- Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatmentBMC Medicine, 2012
- The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic DiseasesThe Open Rheumatology Journal, 2012
- Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signalsBlood, 2010
- Isoform-Specific Phosphoinositide 3-Kinase Inhibitors Exert Distinct Effects in Solid TumorsCancer Research, 2010
- The p110δ structure: mechanisms for selectivity and potency of new PI(3)K inhibitorsNature Chemical Biology, 2010
- Targeting the phosphoinositide 3-kinase pathway in cancerNature Reviews Drug Discovery, 2009
- The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolismNature Reviews Genetics, 2006
- The Phosphoinositide 3-Kinase PathwayScience, 2002